AAAAAA

   
Results: 1-9 |
Results: 9
ECONOMIC-ANALYSIS OF FLUCONAZOLE VERSUS AMPHOTERICIN-B FOR THE TREATMENT OF CANDIDEMIA IN NON-NEUTROPENIC PATIENTS
Authors: DRANITSARIS G PHILLIPS P ROTSTEIN C PUODZIUNAS A SHAFRAN S GARBER G SMAILL F SALIT I MILLER M WILLIAMS K CONLY J SINGER J IOANNOU S
Citation: G. Dranitsaris et al., ECONOMIC-ANALYSIS OF FLUCONAZOLE VERSUS AMPHOTERICIN-B FOR THE TREATMENT OF CANDIDEMIA IN NON-NEUTROPENIC PATIENTS, PharmacoEconomics, 13(5), 1998, pp. 509-518
COST-BENEFIT-ANALYSIS OF PROPHYLACTIC GRANULOCYTE-COLONY-STIMULATING FACTOR DURING CHOP ANTINEOPLASTIC THERAPY FOR NON-HODGKINS-LYMPHOMA
Authors: DRANITSARIS G ALTMAYER C QUIRT I
Citation: G. Dranitsaris et al., COST-BENEFIT-ANALYSIS OF PROPHYLACTIC GRANULOCYTE-COLONY-STIMULATING FACTOR DURING CHOP ANTINEOPLASTIC THERAPY FOR NON-HODGKINS-LYMPHOMA, PharmacoEconomics, 11(6), 1997, pp. 566-577
A PILOT-STUDY TO EVALUATE THE FEASIBILITY OF USING WILLINGNESS-TO-PAYAS A MEASURE OF VALUE IN CANCER SUPPORTIVE CARE - AN ASSESSMENT OF AMIFOSTINE CYTOPROTECTION
Authors: DRANITSARIS G
Citation: G. Dranitsaris, A PILOT-STUDY TO EVALUATE THE FEASIBILITY OF USING WILLINGNESS-TO-PAYAS A MEASURE OF VALUE IN CANCER SUPPORTIVE CARE - AN ASSESSMENT OF AMIFOSTINE CYTOPROTECTION, Supportive care in cancer, 5(6), 1997, pp. 489-499
COST-UTILITY ANALYSIS OF PACLITAXEL IN COMBINATION WITH CISPLATIN FORPATIENTS WITH ADVANCED OVARIAN-CANCER
Authors: ORTEGA A DRANITSARIS G STURGEON J SUTHERLAND H OZA A
Citation: A. Ortega et al., COST-UTILITY ANALYSIS OF PACLITAXEL IN COMBINATION WITH CISPLATIN FORPATIENTS WITH ADVANCED OVARIAN-CANCER, Gynecologic oncology, 66(3), 1997, pp. 454-463
USING FILGRASTIM EFFICIENTLY
Authors: DRANITSARIS G
Citation: G. Dranitsaris, USING FILGRASTIM EFFICIENTLY, PharmacoEconomics, 9(5), 1996, pp. 466-467
PHARMACOECONOMIC ANALYSIS OF EMPIRICAL THERAPY WITH CEFTAZIDIME ALONEOR COMBINATION ANTIBIOTICS FOR FEBRILE NEUTROPENIA IN CANCER-PATIENTS
Authors: DRANITSARIS G TRAN TM MCGEER A NARINE L
Citation: G. Dranitsaris et al., PHARMACOECONOMIC ANALYSIS OF EMPIRICAL THERAPY WITH CEFTAZIDIME ALONEOR COMBINATION ANTIBIOTICS FOR FEBRILE NEUTROPENIA IN CANCER-PATIENTS, PharmacoEconomics, 7(1), 1995, pp. 49-62
ECONOMIC-ANALYSIS OF PROPHYLACTIC G-CSF AFTER MINI-BEAM SALVAGE CHEMOTHERAPY FOR HODGKINS AND NON-HODGKINS-LYMPHOMA
Authors: DRANITSARIS G SUTCLIFFE SB
Citation: G. Dranitsaris et Sb. Sutcliffe, ECONOMIC-ANALYSIS OF PROPHYLACTIC G-CSF AFTER MINI-BEAM SALVAGE CHEMOTHERAPY FOR HODGKINS AND NON-HODGKINS-LYMPHOMA, Leukemia & lymphoma, 17(1-2), 1995, pp. 139-145
ECONOMIC-ANALYSES OF TOXICITY SECONDARY TO ANTHRACYCLINE-BASED BREAST-CANCER CHEMOTHERAPY
Authors: DRANITSARIS G TRAN TM
Citation: G. Dranitsaris et Tm. Tran, ECONOMIC-ANALYSES OF TOXICITY SECONDARY TO ANTHRACYCLINE-BASED BREAST-CANCER CHEMOTHERAPY, European journal of cancer, 31A(13-14), 1995, pp. 2174-2180
A RANDOMIZED TRIAL OF THE EFFECTS OF PHARMACIST INTERVENTION ON THE COST OF ANTIEMETIC THERAPY WITH ONDANSETRON
Authors: DRANITSARIS G WARR D PUODZIUNAS A
Citation: G. Dranitsaris et al., A RANDOMIZED TRIAL OF THE EFFECTS OF PHARMACIST INTERVENTION ON THE COST OF ANTIEMETIC THERAPY WITH ONDANSETRON, Supportive care in cancer, 3(3), 1995, pp. 183-189
Risultati: 1-9 |